New hope for kids with Tough-to-Treat leukemia: experimental combo enters testing
NCT ID NCT04898894
Summary
This study is testing a new combination of oral drugs (selinexor and venetoclax) with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose. Researchers will also see if this combination can help patients achieve remission and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Rady Children's Hospital-San Diego
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
UT Southwestern/Simmons Cancer Center
Dallas, Texas, 75390, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.